EDIT - エディタス・メディシン （Editas Medicine Inc.）

The trading price of Editas Medicine Inc. (NASDAQ:EDIT) closed lower on Monday, February 06, closing at $11.12, -1.24% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $11.005 and $11.4802. In examining the 52-week price action we see that the stock hit a 52-week … Is Editas Medicine Inc.’s (NASDAQ:EDIT) Stock On The Decline? Read More »

The gene-editing biotech''s shares have had a strong two-week run.

Layoffs and a thin clinical-stage pipeline aren''t very encouraging.

CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR, to try to improve human health. Using CRISPR, scientists can slice into DNA, altering it and reducing the negative impact of a variety of maladies. CRISPR-based medicines and therapies are currently being tested as treatments for cancer, neurodegenerative diseases, and other illnesses. CRISPR has come a long way in a short time. An initial paper documenting the phenomenon was published in 2011, and the authors received a Nobel Prize for their work in 2020. Meanwhile, the FDA has started to approve drugs based on the technology. That said, some challenges remain when it comes to using CRISPR. It is expensive and technically challenging to develop certain kinds of therapies based on gene editing. In addition, side effects have been observed, such as those caused by off-target responses, Regardless, money keeps flowing into the gene editing space, and these three CRISPR stocks are worthy of investors’ attention going forward.

The genome-editing company''s shares spiked following a definitive agreement with Shoreline Biosciences last month.

I believe EDIT will be unlikely to catch up with peers with much more advanced clinical studies. See here for upcoming catalysts and key risks facing EDIT.

Editas Medicine ( NASDAQ:EDIT ) Third Quarter 2022 Results Key Financial Results Revenue: US$42.0k (down 99% from 3Q…

Editas Medicine (EDIT) is trading 7% higher after the company posted better-than expected Q3 GAAP EPS. The company recorded collaboration and other research and development revenues…

Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) Q3 2022 Earnings Conference Call November 02, 2022 08:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - Chief…

Other CRISPR companies command multibillion-dollar valuations, but Editas trades below its IPO price following upheaval and clinical delay.

Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022, 10:30 AM ET Company Participants Gilmore O’Neill - President and…

Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) 2022 Wells Fargo Healthcare Conference September 07, 2022 01:55 PM ET Company Participants Gilmore O''Neill - Chief Executive Officer Mark Shearman…

Editas Medicine Inc. (NASDAQ:EDIT) marked $14.30 per share on Tuesday, down from a previous closing price of $14.83. While Editas Medicine Inc. has underperformed by -3.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EDIT fell by -79.05%, with highs and lows ranging from $72.50 to […]

In last trading session, Editas Medicine Inc. (NASDAQ:EDIT) saw 1.31 million shares changing hands with its beta currently measuring 2.04. Company’s recent per share price level of $15.42 trading at $0.72 or 4.90% at ring of the bell on the day assigns it a market valuation of $1.16B. That closing price of EDIT’s stock is … Editas Medicine Inc. (NASDAQ:EDIT) Could Actually Go To $80.00 In 12 Months Read More »

Editas Medicine''s engraftment trial experiment made positive headway in Q2 2022. Click here to see EDIT''s growth prospects and potential risks.